President Donald J. Trump officially launched TrumpRx.gov, a new federal platform designed to provide Americans with direct access to dramatically lower prices on dozens of high-cost, brand-name prescription drugs.
The platform is built on landmark Most-Favored-Nation pricing agreements negotiated with leading pharmaceutical manufacturers, aligning U.S. drug prices with the lowest paid in other developed nations. Administration officials said the initiative ends decades of overpayment by American patients and delivers immediate financial relief, particularly for those facing high out-of-pocket costs for medications not fully covered by insurance.
Starting today, patients can access substantially reduced prices on dozens of essential drugs through TrumpRx.gov. Additional high-cost medications are expected to be added on a rolling basis as the administration continues to pursue new agreements with pharmaceutical companies.
Among the most significant reductions are GLP-1 medications, which represent some of the highest drug spending in the United States.
Under the new pricing:
-
Monthly costs for Ozempic® and injectable Wegovy® drop from $1,028 and $1,349, respectively, to an average of $350 and as low as $199, depending on dosage.
-
The monthly price of the Wegovy® pill falls from $1,349 to as low as $149, depending on dosage.
-
The monthly price of Zepbound® decreases from $1,088 to an average of $346 and as low as $299, depending on dosage.
The platform also delivers major savings for Americans undergoing fertility treatments, which are often paid for entirely out-of-pocket. Administration officials estimate patients could save more than $2,000 per treatment cycle on commonly used fertility medications.
Under TrumpRx.gov pricing:
-
Gonal-F®, one of the most widely used fertility drugs, falls to as low as $168 per pen, depending on dosage.
-
Cetrotide® drops from $316 to $22.50.
-
Ovidrel® falls from $251 to $84.
Officials said the Trump Administration is actively onboarding additional pharmaceutical companies with Most-Favored-Nation agreements and is aggressively pursuing new deals to expand the platform’s offerings. The goal, they said, is to drive even greater savings for American patients and permanently lower prescription drug costs across the healthcare system.
The launch of TrumpRx.gov marks a central pillar of the administration’s broader effort to reduce healthcare costs and put American consumers first by leveraging the government’s negotiating power to secure the best possible prices.